This review highlights the current lack of understanding regarding the wider actions of heparin in pregnancy and raises concerns about its potential inappropriate use.
Answers are grounded in this paper and cite their sources.
Clinicians should restrict heparin to proven indications in pregnancy; leaves open its broader mechanisms and optimal use.
The development of effective anticoagulant drugs available for use in pregnancy has resulted in dramatic improvements for a number of potentially life-threatening conditions. These include the treatment and prevention of venous thromboembolism and the thrombotic complications of antiphospholipid antibody syndrome, as well as the management of pregnant women with mechanical heart valves. The most commonly used class of drug includes heparin, a highly-charged macro-molecule that does not cross the placenta, in contrast to the potentially teratogenic and fetotoxic oral drug warfarin. This review will focus on our current lack of understanding of the wider actions of heparin and examines the possibility that large numbers of pregnant women are presently being treated inappropriately with heparin.
No takes yet. Share an insight, caveat, or question.
Drewlo et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: